Securing sustainable funding for viral hepatitis elimination plans

Angelos Hatzakis, Jeffrey V. Lazarus, Evangelos Cholongitas, Ricardo Baptista-Leite, Charles Boucher, Cristian-Silviu Busoi, Sylvie Deuffic-Burban, Jagpreet Chhatwal, Gamal Esmat, Sharon Hutchinson, Minerva-Melpomeni Malliori, Mojca Maticic, Antons Mozalevskis, Francesco Negro, George A. Papandreou, George V. Papatheodoridis, Markus Peck-Radosavljevic, Homie Razavi, Tatjana Reic, Eberhard SchatzNurdan Tozun, Zobair Younossi, Michael P. Manns

Research output: Contribution to journalArticle

Abstract

The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580,000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling-up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.
Original languageEnglish
Pages (from-to)260-270
Number of pages10
JournalLiver International
Volume40
Issue number2
Early online date5 Dec 2019
DOIs
Publication statusPublished - Feb 2020

Fingerprint

Hepacivirus
Hepatitis
European Union
Harm Reduction
Eastern Europe
Emigration and Immigration
Chronic Hepatitis C
Financial Management
Virus Diseases
Public Policy
Hepatitis C
Hepatitis B
Antiviral Agents
Economics
Costs and Cost Analysis
Health
Therapeutics

Keywords

  • Prevention
  • burden
  • care
  • elimination
  • health policy
  • viral hepatitis
  • high-risk populations
  • treatment
  • surveillance

Cite this

Hatzakis, A., Lazarus, J. V., Cholongitas, E., Baptista-Leite, R., Boucher, C., Busoi, C-S., ... Manns, M. P. (2020). Securing sustainable funding for viral hepatitis elimination plans. Liver International, 40(2), 260-270. https://doi.org/10.1111/liv.14282
Hatzakis, Angelos ; Lazarus, Jeffrey V. ; Cholongitas, Evangelos ; Baptista-Leite, Ricardo ; Boucher, Charles ; Busoi, Cristian-Silviu ; Deuffic-Burban, Sylvie ; Chhatwal, Jagpreet ; Esmat, Gamal ; Hutchinson, Sharon ; Malliori, Minerva-Melpomeni ; Maticic, Mojca ; Mozalevskis, Antons ; Negro, Francesco ; Papandreou, George A. ; Papatheodoridis, George V. ; Peck-Radosavljevic, Markus ; Razavi, Homie ; Reic, Tatjana ; Schatz, Eberhard ; Tozun, Nurdan ; Younossi, Zobair ; Manns, Michael P. / Securing sustainable funding for viral hepatitis elimination plans. In: Liver International. 2020 ; Vol. 40, No. 2. pp. 260-270.
@article{2dd807b3664c4145baf01510aab86597,
title = "Securing sustainable funding for viral hepatitis elimination plans",
abstract = "The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580,000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling-up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.",
keywords = "Prevention, burden, care, elimination, health policy, viral hepatitis, high-risk populations, treatment, surveillance",
author = "Angelos Hatzakis and Lazarus, {Jeffrey V.} and Evangelos Cholongitas and Ricardo Baptista-Leite and Charles Boucher and Cristian-Silviu Busoi and Sylvie Deuffic-Burban and Jagpreet Chhatwal and Gamal Esmat and Sharon Hutchinson and Minerva-Melpomeni Malliori and Mojca Maticic and Antons Mozalevskis and Francesco Negro and Papandreou, {George A.} and Papatheodoridis, {George V.} and Markus Peck-Radosavljevic and Homie Razavi and Tatjana Reic and Eberhard Schatz and Nurdan Tozun and Zobair Younossi and Manns, {Michael P.}",
note = "Acceptance in SAN AAM version queried 29/10/19 DC ^Removed first few pages and re-uploaded. ET 4/12/19 AAM: 12m embargo",
year = "2020",
month = "2",
doi = "10.1111/liv.14282",
language = "English",
volume = "40",
pages = "260--270",
number = "2",

}

Hatzakis, A, Lazarus, JV, Cholongitas, E, Baptista-Leite, R, Boucher, C, Busoi, C-S, Deuffic-Burban, S, Chhatwal, J, Esmat, G, Hutchinson, S, Malliori, M-M, Maticic, M, Mozalevskis, A, Negro, F, Papandreou, GA, Papatheodoridis, GV, Peck-Radosavljevic, M, Razavi, H, Reic, T, Schatz, E, Tozun, N, Younossi, Z & Manns, MP 2020, 'Securing sustainable funding for viral hepatitis elimination plans', Liver International, vol. 40, no. 2, pp. 260-270. https://doi.org/10.1111/liv.14282

Securing sustainable funding for viral hepatitis elimination plans. / Hatzakis, Angelos; Lazarus, Jeffrey V.; Cholongitas, Evangelos; Baptista-Leite, Ricardo; Boucher, Charles; Busoi, Cristian-Silviu; Deuffic-Burban, Sylvie; Chhatwal, Jagpreet; Esmat, Gamal; Hutchinson, Sharon; Malliori, Minerva-Melpomeni; Maticic, Mojca; Mozalevskis, Antons; Negro, Francesco; Papandreou, George A.; Papatheodoridis, George V.; Peck-Radosavljevic, Markus; Razavi, Homie; Reic, Tatjana; Schatz, Eberhard; Tozun, Nurdan; Younossi, Zobair; Manns, Michael P.

In: Liver International, Vol. 40, No. 2, 02.2020, p. 260-270.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Securing sustainable funding for viral hepatitis elimination plans

AU - Hatzakis, Angelos

AU - Lazarus, Jeffrey V.

AU - Cholongitas, Evangelos

AU - Baptista-Leite, Ricardo

AU - Boucher, Charles

AU - Busoi, Cristian-Silviu

AU - Deuffic-Burban, Sylvie

AU - Chhatwal, Jagpreet

AU - Esmat, Gamal

AU - Hutchinson, Sharon

AU - Malliori, Minerva-Melpomeni

AU - Maticic, Mojca

AU - Mozalevskis, Antons

AU - Negro, Francesco

AU - Papandreou, George A.

AU - Papatheodoridis, George V.

AU - Peck-Radosavljevic, Markus

AU - Razavi, Homie

AU - Reic, Tatjana

AU - Schatz, Eberhard

AU - Tozun, Nurdan

AU - Younossi, Zobair

AU - Manns, Michael P.

N1 - Acceptance in SAN AAM version queried 29/10/19 DC ^Removed first few pages and re-uploaded. ET 4/12/19 AAM: 12m embargo

PY - 2020/2

Y1 - 2020/2

N2 - The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580,000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling-up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.

AB - The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580,000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling-up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.

KW - Prevention

KW - burden

KW - care

KW - elimination

KW - health policy

KW - viral hepatitis

KW - high-risk populations

KW - treatment

KW - surveillance

U2 - 10.1111/liv.14282

DO - 10.1111/liv.14282

M3 - Article

VL - 40

SP - 260

EP - 270

IS - 2

ER -

Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi C-S et al. Securing sustainable funding for viral hepatitis elimination plans. Liver International. 2020 Feb;40(2):260-270. https://doi.org/10.1111/liv.14282